Trial Profile
A RANDOMIZED, DOUBLE BLIND, MULTIPLE DOSING (14 DAYS), PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER, MULTI CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF THREE DOSE LEVELS OF AZD7594, GIVEN ONCE DAILY BY INHALATION, IN PATIENTS WITH MILD TO MODERATE ASTHMA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Velsecorat (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 13 Nov 2015 Planned End Date changed from 1 May 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 13 Nov 2015 Planned primary completion date changed from 1 May 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.